Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multicohort study of ciltacabtagene autoleucel in transplant-ineligible newly diagnosed multiple myeloma
2025-521975-30-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: MRD-negative complete response at 12 months. Planned start Aug 2025; status: authorised.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-521975-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521975-30-00.